ACE2 and COVID-19: Canrenone may exert some of its positive effects following the theory that spironolactone may provide protection against SARS-CoV-2-induced acute respiratory distress syndrome through different mechanisms: (i) By increasing the plasma levels of circulating ACE2, thereby limiting its attachment to cellular ACE2, (ii) by downregulating the testosterone-mediated expression of transmembrane serine protease 2 (TMPRSS2), and (iii) by a direct anti-inflammatory and antiviral effect that could avoid pulmonary complications related to COVID-19 (discussed in [17,18,19]).